Fig. 5
From: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome
Agonism of the adenosine A2A receptor mitigates venous thrombosis in control mice. a Neutrophils were prepared from the bone marrow of C57BL/6 mice and then treated with control IgG or APS IgG. Some samples were additionally treated with CGS21680. NETosis was quantified by immunofluorescence microscopy. Mean and standard deviation are presented for n = 3 independent experiments; ***p < 0.001 by one-way ANOVA corrected with Sidak’s test. b Schematic of the flow-restriction model of venous thrombosis. The inferior vena cava is narrowed by fixing a ligature around the IVC (using a spacer, which is then removed). When a thrombus forms, it is just caudal to the stenosis in the area indicated by the spiral. Thrombus formation was assessed at 48 h for all of the following experiments. c–e Thrombus incidence (c), thrombus weight (d), and thrombus length (e) were assessed for C57BL/6 wild-type mice subjected to the flow-restriction model. Some mice were treated with the adenosine A2A receptor agonist CGS21680 as indicated. Each data point represents a unique mouse, while horizontal lines denote mean values; *p < 0.05 and **p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t-test for panels d and e). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; *p < 0.05 as compared with the control group. g–i Thrombus incidence (g), thrombus weight (h), and thrombus length (i) were assessed for mice subjected to the flow-restriction model. Some mice were treated with dipyridamole as indicated; *p < 0.05 as compared with the control group (Chi-square test for panel g and unpaired t-test for panels h and i). j Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; *p < 0.05 as compared with the control group by unpaired t-test
